Absorption; Chemicals Clinical Trial
Official title:
A Pilot Study to Determine the Bioavailability of Oral Beta-Aminoisobutyric Acid (BAIBA) Ingestion
Think of this section as your research "elevator pitch." Please briefly describe the question(s) or issues you are addressing with your research (limited to 100 words). You will be able to provide information on specific outcomes, hypothesis, or related analysis in a following question. Beta-amino isobutyric acid (BAIBA) is a myokine produced in skeletal muscle and has been shown to impact how our body metabolizes fuel. We seek to determine the bioavailability of different doses of orally ingested beta-aminoisobutyric acid (BAIBA).
Once determined eligible and provided consent, participants will be assigned in a randomized, double-blind, placebo-controlled, crossover fashion. Eligible study participants will complete one of five testing conditions outlined below. For each testing condition, study participants will arrive in the lab after observing an overnight fast. Upon arrival, participants will donate the first of seven venous blood samples. Follow-up blood samples will be collected at 30, 60, 90, 120, 240, 300 minutes. The first and last collected samples will be collected into one 8mL SST and three 4mL EDTA tubes, while the second, third, and forth collected samples will be into two 4mL EDTA tubes, and have aliquots of 600 ul of plasma isolated and frozen at -80oC. Collected plasma will be analyzed for changes in beta-aminoisobutyric acid (BAIBA) and biomarkers commonly assessed by physicians to evaluate healthy. Participants will observe a minimum of 48 hours washout between conditions. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04078646 -
Influence of Proteins on the Bioavailability of Carotenoids
|
N/A | |
| Completed |
NCT04355286 -
Bemotrizinol UV Filter Part 1 Clinical PK Evaluation in Topical MUsT Study
|
Phase 1 | |
| Completed |
NCT03807050 -
Safety and Pharmacokinetics of Phaffia Rhodozyma Astaxanthin
|
N/A | |
| Active, not recruiting |
NCT02227615 -
Absorption of Mango in Healthy Individuals
|
N/A | |
| Completed |
NCT05277376 -
Pharmacokinetic (PK) Evaluation of Bemotrizinol (6%) in a Sunscreen Maximum Usage Trial
|
Phase 3 | |
| Completed |
NCT05032807 -
Pharmacokinetic Study of a Novel Lipid Formulation of Cannabidiol Compared to a Standard Formulation
|
Phase 1 | |
| Completed |
NCT05076890 -
Hemp 15 mg & 50 mg Capsule Absorption
|
N/A | |
| Completed |
NCT03433040 -
17OHP-C Dosing Among Obese Pregnant Women
|
Phase 3 |